ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
Among patients with muscle-invasive bladder cancer, ctDNA-guided adjuvant therapy with atezolizumab led to significantly longer disease-free survival and overall survival than placebo. (Funded by F. Hoffmann-La Roche; IMvigor011 ClinicalTrials.gov number, NCT04660344.).
Authors
- Ja Hyeon Ku (ORCID: https://orcid.org/0000-0002-0391-2342)
- Marine Gross‐Goupil (ORCID: https://orcid.org/0000-0002-3176-4076)
- Òscar Reig (ORCID: https://orcid.org/0000-0003-1166-6943)
- Daniel Castellano (ORCID: https://orcid.org/0000-0002-9106-0687)
- Łukasz Dołowy
- Marco Maruzzo (ORCID: https://orcid.org/0000-0002-6256-9249)
- Giampaolo Tortora (ORCID: https://orcid.org/0000-0002-1378-4962)
- Se Hoon Park (ORCID: https://orcid.org/0000-0001-5084-9326)
- Zoe J. Assaf (ORCID: https://orcid.org/0000-0002-3469-6697)
- Sergio Bracarda (ORCID: https://orcid.org/0000-0002-0703-2959)
- Jae‐Lyun Lee (ORCID: https://orcid.org/0000-0002-9420-7162)
- Yüksel Ürün (ORCID: https://orcid.org/0000-0002-9152-9887)
- Jürgen E. Gschwend (ORCID: https://orcid.org/0000-0003-1812-5103)
- Ariel Galapo Kann (ORCID: https://orcid.org/0000-0002-7260-2030)
- Rafael Morales‐Barrera (ORCID: https://orcid.org/0000-0001-7398-0685)
- Hiroyuki Nishiyama (ORCID: https://orcid.org/0000-0001-7423-596X)
- Joaquim Bellmunt (ORCID: https://orcid.org/0000-0003-2328-3421)
- Lydia Makaroff (ORCID: https://orcid.org/0000-0001-7381-5743)
- F. Pontes Grando
- Jacqueline Vuky (ORCID: https://orcid.org/0000-0001-5795-3361)
- Viraj Degaonkar
- Andrea Necchi (ORCID: https://orcid.org/0000-0002-3007-2756)
- Emilio Francesco Giunta (ORCID: https://orcid.org/0000-0002-5383-4469)
- Wei Zou (ORCID: https://orcid.org/0000-0002-3639-9821)
- Elizabeth E. Steinberg (ORCID: https://orcid.org/0000-0002-4879-1935)
- Thomas B. Powles (ORCID: https://orcid.org/0000-0001-7760-4724)
- Álvaro Pinto (ORCID: https://orcid.org/0000-0002-4719-053X)
- Jørgen Bjerggaard Jensen (ORCID: https://orcid.org/0000-0002-4347-739X)
- Di̇lek Erdem (ORCID: https://orcid.org/0000-0001-6495-6712)
- Dingwei Ye (ORCID: https://orcid.org/0000-0003-4974-3780)
- Shusuan Jiang
Institutions
- Università Cattolica del Sacro Cuore (IT)
- Ulsan College (KR)
- Hebron University (PS)
- University of Tsukuba (JP)
- Ankara University (TR)
- Université de Bordeaux (FR)
- Vita-Salute San Raffaele University (IT)
- Queen Mary University of London (GB)
- Aarhus University (DK)
- Hospital Universitario La Paz (ES)
- Asan Medical Center (KR)
- Samsung Medical Center (KR)
- Agostino Gemelli University Polyclinic (IT)
- Seoul National University Hospital (KR)
- University of Ulsan (KR)
- Fudan University Shanghai Cancer Center (CN)
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT)
- Hospital Alemão Oswaldo Cruz (BR)
- Hospital Universitario 12 De Octubre (ES)
- Mylan (South Africa) (ZA)
- Istituto Oncologico Veneto (IT)
- Hunan Cancer Hospital (CN)
- Dana-Farber Cancer Institute (US)
- Istinye University (TR)
- Azienda Ospedaliera S.Maria (IT)
- IRCCS Ospedale San Raffaele (IT)
- Dana-Farber/Harvard Cancer Center (US)
- Central Clinical Hospital (PL)
- Bladder Cancer Advocacy Network (US)
- Istituti di Ricovero e Cura a Carattere Scientifico (IT)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Centro de Pesquisas Oncológicas (BR)
- Vall d'Hebron Institute of Oncology (ES)
- Sungkyunkwan University (KR)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-10-20
- DOI
- https://doi.org/10.1056/nejmoa2511885
- Citations
- 47
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 94.30